Table 2.
Baseline Characteristics of Patients After Propensity Score Matching
| Characteristics | Total (N =68) | Atezo/Bev-TACE Group (n = 34) | LEN-TACE Group (n = 34) | P value |
|---|---|---|---|---|
| Age, years, median (IQR) | 55.0 (47.0–63.8) | 55.0 (42.0–62.0) | 55.0 (48.8–66.0) | 0.449 |
| Gender, n (%) | ||||
| Male | 59 (86.8) | 29 (85.3) | 30 (88.2) | 1.000 |
| Female | 9 (13.2) | 5 (14.7) | 4 (11.8) | |
| ECOG performance status, n (%) | ||||
| 0 | 49 (72.1) | 23 (67.6) | 26 (76.5) | 0.417 |
| 1 | 19 (27.9) | 11 (32.4) | 8 (23.5) | |
| Etiology, n (%) | ||||
| Hepatitis B | 62 (91.2) | 31 (91.2) | 31 (91.2) | 1.000 |
| Other | 3 (8.8) | 3 (8.8) | 3 (8.8) | |
| No. of nodules, n (%) | ||||
| 1 | 14 (20.6) | 5 (14.7) | 9 (26.5) | 0.401 |
| 2 | 13 (19.1) | 6 (17.6) | 7 (20.6) | |
| ≥3 | 41 (60.3) | 23 (67.6) | 18 (52.9) | |
| BCLC stage, n (%) | ||||
| B | 14 (20.6) | 5 (14.7) | 9 (26.5) | 0.230 |
| C | 54 (79.4) | 29 (85.3) | 25 (73.5) | |
| Portal vein tumor thrombus, n (%) | ||||
| Absent | 22 (32.4) | 11 (32.4) | 11 (32.4) | 0.344 |
| Vp-1 and 2 | 19 (27.9) | 10 (29.4) | 9 (26.5) | |
| Vp-3 | 11 (16.2) | 3 (8.8) | 8 (23.5) | |
| Vp-4 | 16 (23.5) | 10 (29.4) | 6 (17.6) | |
| Largest nodule, mean ± SE | 97.9±42.3 | 96.5±46.0 | 99.4±38.8 | 0.787 |
| Child–Pugh class, n (%) | ||||
| A5 | 51 (75.0) | 24 (70.6) | 27 (79.4) | 0.401 |
| A6 | 17 (25.0) | 10 (29.4) | 7 (20.6) | |
| ALBI grade, n (%) | ||||
| 1 | 36 (52.9) | 17 (50.0) | 19 (55.9) | 0.627 |
| 2 | 32 (47.1) | 17 (50.0) | 15 (44.1) | |
| Extrahepatic spread, n (%) | ||||
| Absent | 55 (80.9) | 26 (76.5) | 29 (85.3) | 0.774 |
| Present | 13 (19.1) | 8 (23.5) | 5 (14.7) | |
| Lung | 5 (7.4) | 3 (8.8) | 2 (5.9) | |
| Lymph nodes | 4 (5.9) | 3 (8.8) | 1 (2.9) | |
| Other | 4 (5.9) | 2 (5.9) | 2 (5.9) | |
| Time between first TACE and initiation of systemic therapy, days, median (IQR) | 5.0 (3.0–8.8) | 5.0 (2.0–8.3) | 5.5 (3.0–9.0) | 0.395 |
| AFP, n (%) | ||||
| ≤400 ng/mL | 32 (47.1) | 16 (47.1) | 16 (47.1) | 1.000 |
| >400 ng/mL | 36 (52.9) | 18 (52.9) | 18 (52.9) | |
| TBIL, μmol/mL, median (IQR) | 12.1 (9.3–16.5) | 11.0 (8.2–16.7) | 12.7 (9.8–16.6) | 0.620 |
| AST, U/L, median (IQR) | 47.0 (32.5–72.3) | 54.5 (30.0–78.8) | 42.0 (34.8–68.3) | 0.169 |
| ALT, U/L, median (IQR) | 36.0 (24.3–53.0) | 35.5 (21.8–48.5) | 36.5 (26.0–56.0) | 0.791 |
| Albumin, g/L, mean ± SE | 38.7±4.0 | 38.4±4.2 | 39.1±3.8 | 0.514 |
| WBC, ×109/L, mean ± SE | 6.0±1.9 | 5.9±1.8 | 6.0±2.0 | 0.935 |
| Platelet, ×109/L, mean ± SE | 203.3±92.3 | 203.6±91.2 | 203.0±94.7 | 0.979 |
| PT, seconds, mean ± SE | 13.8±1.0 | 13.9±0.8 | 13.7±1.3 | 0.283 |
| INR, median (IQR) | 1.04 (0.99–1.09) | 1.05 (1.01–1.12) | 1.03 (0.99–1.07) | 0.062 |
| Creatinine, umol/L, median (IQR) | 70.5 (59.9–80.0) | 70.0 (63.0–81.0) | 71.0 (57.8–79.5) | 0.668 |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; AFP, alpha-fetoprotein; TBIL, total bilirubin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; WBC, white blood cell; INR, international normalized ratio; BCLC, Barcelona Clinic Liver Cancer; IQR, interquartile range; TACE, transarterial chemoembolization; Atezo/Bev, Atezolizumab plus Bevacizumab; LEN, lenvatinib.